Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Earnings Data
Report Date
Jun 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.19Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 10, 2025
|% Change Since: -1.56%
|Next Earnings Date:Jun 25, 2025
Earnings Call Sentiment|Neutral
Roivant Sciences Ltd. discussed a strong financial position and a promising pipeline with several upcoming clinical milestones. However, the company faces challenges in ongoing litigation and a competitive landscape in certain areas.Company Guidance
During the Roivant Sciences Ltd. third quarter 2024 earnings call, CEO Matt Gline highlighted several key metrics and developments. The company is set to advance its API CRM franchise with imminent data for MG and CIDP, along with a registrational readout in dermatomyositis that could lead to the commercial launch of brepasitinib. A new trial for brepasitinib in cutaneous sarcoidosis is also in the pipeline. Roivant reported a cash balance of $5.2 billion as of December 31, 2024, including $500 million authorized for additional share buybacks. The company has cleared six INDs at Abutavant, with ongoing trials and plans to initiate more by March 2026. Roivant is also engaged in significant LNP litigation with Moderna and Pfizer BioNTech, with major court phases scheduled for 2025. The company aims to achieve ten-plus indication blockbuster launches, anchored by its diversified late-stage biotech pipeline.Strong Cash Position
Roivant Sciences has a cash balance of $5.2 billion as of December 31, 2024. This includes $500 million authorized for additional share buybacks and significant cash inflow from the sale of dermaVant to Organon.
Significant Pipeline Developments
Roivant highlighted its strong pipeline with multiple late-stage biotech programs, including brepasitinib with a new indication in cutaneous sarcoidosis and a planned trial start this year.
Upcoming Clinical Milestones
The company is expecting important clinical data readouts in 2025, including registrational readouts for dermatomyositis and other significant milestones in MG and CIDP.
---
ROIV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ROIV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 10, 2025 | $10.89 | $10.79 | -0.92% |
| Nov 12, 2024 | $11.81 | $11.64 | -1.44% |
| Aug 08, 2024 | $10.17 | $10.85 | +6.69% |
| May 30, 2024 | $10.73 | $10.39 | -3.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roivant Sciences (ROIV) report earnings?
Roivant Sciences (ROIV) is schdueled to report earning on Jun 25, 2025, TBA Not Confirmed.
What is Roivant Sciences (ROIV) earnings time?
Roivant Sciences (ROIV) earnings time is at Jun 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ROIV EPS forecast?
ROIV EPS forecast for the fiscal quarter 2024 (Q4) is -0.26.
---